INTS — Intensity Therapeutics, Inc.

Is INTS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Intensity Therapeutics, Inc. (INTS) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $3.07. The rating moved from Strong Oversold to Oversold on November 14, 2026.

See all oversold Healthcare stocks →

AI analysis

Intensity Therapeutics, Inc. shows characteristics of an early‑stage, small‑cap therapeutic developer where valuation is highly sensitive to clinical, regulatory and financing events. Limited public disclosure and absent social/research coverage increase uncertainty. Near‑term upside depends on positive data, partnering or clear non‑dilutive financing; downside is driven by cash‑runway pressures, potential dilution and clinical/regulatory setbacks. Current market flows favor larger, defensive pharma which creates a headwind for speculative biotech exposure. Monitor filings, cash runway updates, and any announced milestones; absent clear near‑term catalysts or financing clarity, expect elevated volatility and constrained liquidity.

Key factors

  • Small-cap biopharma profile with likely limited public financial disclosures and a binary outcomes profile tied to clinical and regulatory milestones
  • Near-term catalysts could include clinical data readouts, partnering/licensing discussions or non-dilutive financing that would materially change valuation
  • Sector flows favor large-cap pharma and defensive healthcare, which can reduce investor appetite for early-stage/volatile biotech names
  • Market-wide risk-on tone for earnings momentum may help speculative names in the short term but provides limited fundamental support
  • Convertible-debt and broader biotech financing environment increases the probability of dilution or hedging-related selling pressure for mid-/small-cap issuers
  • Information vacuum on recent filings and social sentiment elevates uncertainty and pricing volatility

Risks

  • Cash runway and near-term financing needs are unclear; potential for dilutive equity raises or convertible issuances
  • Clinical trial failures, negative safety signals or regulatory setbacks would be materially negative and could sharply depress the share price
  • Low liquidity and thin trading typical of small-cap biotech can amplify price moves and make exits difficult for holders
  • Competition from better-funded large-cap pharma and platform competitors may limit commercial prospects if later-stage success is achieved
  • Broader sector rotation into large-cap defensive healthcare could reduce available investor capital for early-stage therapeutics
  • Lack of recent EDGAR disclosures and limited social/research coverage increases information asymmetry and execution risk

See today's live rating, score and targets

Members see the live hourly rating for INTS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.